It was a good day for Novartis: A second drug with huge selling potential has been approved for the US market....
Up To Date
Latest News
The FDA has approved Novartis-subsidiary AveXis Inc's spinal muscular atrophy (SMA) gene therapy Zolgensma...
At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report,...
Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera...
EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.